2020ZFB010, and the Foundation of State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers (2025GTEP016)
Because tirzepatide activates a broader receptor footprint, it is studied as a model for combinatorial incretin pharmacology rather than single-pathway agonism
What this means for DFU care: Their anti-inflammatory, vascular, and neuroprotective properties could make GLP-1 receptor agonists a valuable adjunctive therapy in managing complex, chronic diabetic foot ulcers a hypothesis worth further exploration
Treatment is subcutaneous and clinician-monitored
Breastfeeding data remain limited
We also carefully monitor patients for potential side effects, such as cardiovascular issues, sleep apnea, and prostate health concerns, ensuring that the benefits of TRT outweigh any risks